GLP-1R agonists cannot be currently recommended as targeted approaches for MASH but should be administered for their indications (T2D, obesity)
Megalin is expressed along the apical aspect of proximal tubules, where it is responsible for hepatocyte-derived AGT reabsorption and its homeostasis in kidney
It has shown potential to support tissue repair, reduce inflammation, and promote gut health by enhancing the bodys own healing response
[4] [6] This relationship is bidirectional and complex, involving: Inflammatory pathways that affect both metabolic and mental health Hormonal dysregulation impacting mood and stress responses Psychosocial factors including stigma, body image concerns, and chronic disease burden Lifestyle factors such as reduced physical activity and poor sleep quality When GLP-1 medications improve glycaemic control, facilitate weight loss, and enhance overall metabolic health, patients may experience secondary improvements in psychological wellbeing
A 2025 joint advisory published in the American Journal of Clinical Nutrition and narrative reviews recommend GLP-1 users consume 1.21.6 grams of protein per kilogram of body weight daily, with intake distributed evenly across meals
